



Financial Tear Sheet


Corporate Profile

Athenex is a global oncology focused biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, aiming to develop safer and more efficacious cancer medication.

Founded in 2003 and based in Buffalo, New York, our mission is to improve the lives of cancer patients by creating more effective, safer and tolerable treatments. We are focused on generating clinical candidates focused on oral delivery, and currently have seven products including two currently in Phase 3 studies.

Our seasoned management team has a proven track record in drug development and commercialization, including several former industry CEOs. We have the experience and capabilities to leverage our proprietary research and development platforms to produce candidates and move them throughout candidacy to market.

We have organized our business model into three segments: Oncology Innovation Platform, Commercial Platform and Global Supply Chain Platform—with operations in both the U.S. and China. Our global operations across the three segments are shown below:



Our Global Supply Chain Platform manufactures active pharmaceutical ingredients, or API, for use internally in our research and development, clinical studies, and for sale to pharmaceutical customers globally. Our Commercial Platform currently markets the API produced by our Global Supply Chain Platform, including 14 products in the specialty and generic market segment in the U.S. and products under Section 503B of the Food, Drug and Cosmetics Act, or FDCA, through our compound pharmacy facility.

Primary IR Contact

Tim McCarthy
Managing Director, LifeSci Advisors, LLC
Tel: +1 716-427-2952
Direct: +1 212-915-2564

Athenex, Inc.:

Randoll Sze
Chief Financial Officer
Email: randollsze@athenex.com

Jacqueline Li
Email: jacquelineli@athenex.com

Stock Performance

ATNX (Common Stock)

Exchange NASDAQ GS (US Dollar)

Price **\$12.64**

Change (%) **▲ 0.14 (1.12%)**

Volume 168,185

52 Week High \$20.90

52 Week Low \$9.83

Market Cap \$845,538,681

Rolling EPS -1.29

PE Ratio 0

Shares Outstanding 66,893,883

Data as of Feb 15, 2019 4:00 p.m. ET



Recent Headlines

February 14, 2019

[Athenex, Inc. to Report Fourth Quarter and Fiscal Year 2018 Earnings Results on March 11, 2019](#)

February 04, 2019

[Athenex Announces Late-Breaking Oral Presentation of KX2-391 Ointment in Two Phase III Studies at the American Academy of Dermatology Annual Meeting](#)

January 09, 2019

[Athenex Announces Completion of Target Enrollment in the Oraxol Phase III Study](#)

SEC Filings

Filing Date	Form
Feb 14, 2019	SC 13G/A
Feb 12, 2019	SC 13G/A
Feb 08, 2019	SC 13G
Jan 03, 2019	8-K

Upcoming Events

Date	Title
Mar 11, 2019 8:30 a.m. ET	Q4 2018 Athenex, Inc. Earnings Conference Call

Corporate Governance

Data provided by Nasdaq. Minimum 15 minutes delayed.